Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044179 | 0.87 | CA1 (0.51) | ERN1MAPTRAB9AABCG2FFAR2 | |
| SCHEMBL29788180 | 0.87 | CA1 (0.51) | ERN1MAPTRAB9AABCG2FFAR2 | |
| SCHEMBL6773146 | 0.85 | KDM4E (0.56) | ERN1MAPTKMT2AMEN1 | |
| SCHEMBL29868499 | 0.85 | KDM4E (0.56) | ERN1MAPTKMT2AMEN1 | |
| SCHEMBL12599367 | 0.81 | ALDH1A1 (0.56) | ERN1MAPTSMN1; SMN2RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27586476 | 0.80 | ALDH1A1 (0.55) | ERN1MAPTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL12900885 | 0.79 | LMNA (0.52) | MAPTSMN1; SMN2RAB9AALDH1A1HSD17B1 | |
| SCHEMBL12900881 | 0.79 | L3MBTL1 (0.53) | MAPTSMN1; SMN2HSD17B1KMT2AMEN1 | |
| SCHEMBL29364192 | 0.77 | HDAC4 (0.53) | ERN1MAPTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL1370802 | 0.77 | HDAC4 (0.53) | ERN1MAPTSMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673814-B2 | CONTROLLED-RELEASE BY IMPLANTABLE DEVICES, DELIVERY PUMPS, WAFERS, AND BIODEGRADABLE POLYMERS | EMORY UNIVERSITY | 2004-01-06 | — | — | US | disclosed |
| US-20020137762-A1 | Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents | EMORY UNIVERSITY | 2002-09-26 | — | — | US | disclosed |
| US-6376516-B1 | FOR TREATING NEOPLASTIC CANCERS INCLUDING COLON, LUNG, BRAIN, OVARIAN, PROSTATE, BREAST, AND BLADDER CANCER AND LEUKEMIA; LOW TOXICITY | EMORY UNIVERSITY | 2002-04-23 | — | — | US | disclosed |
| WO-1999008528-A1 | NOSCAPINE DERIVATIVES, USEFUL AS ANTICANCER AGENTS | EMORY UNIVERSITY (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137762-A1 | Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents | NOS1, NOS2, HCCS | ERN1 3009/4885MAPT 3083/4885SMN1; SMN2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.